Showing results (151-160 of 208) with videos related to
Sort By:
Pageof 21
Annals of Surgical Oncology|June 26, 2016
Patterns of Clinical Response with Talimogene Laherparepvec (T-VEC) in Patients with Melanoma Treated in the OPTiM Phase III Clinical TrialRobert H I Andtbacka, Merrick Ross, Igor Puzanov, et al.Oncoimmunology|October 15, 2021
An Open-Label, Randomized, Multi-Center Study Comparing the Sequence of High Dose Aldesleukin (Interleukin-2) and Ipilimumab (Yervoy) in Patients with Metastatic MelanomaMerve Hasanov, Denái R Milton, William H Sharfman, et al.Antioxidants (Basel, Switzerland)|May 25, 2024
Superoxide Dismutase Mimetic Avasopasem Manganese Enhances Radiation Therapy Effectiveness in Soft Tissue Sarcomas and Accelerates Wound HealingAmira Zaher, Kranti A Mapuskar, Michael S Petronek, et al.The Journal of Urology|July 26, 2024
Early Prostate-Specific Antigen Response by 6 Months Is Predictive of Treatment Effect in Metastatic Hormone Sensitive Prostate Cancer: An Exploratory Analysis of the TITAN TrialSoumyajit Roy, Yilun Sun, Kim N Chi, et al.JCO Oncology Practice|May 29, 2026
Development and External Validation of a Machine Learning-Based Risk Classification Score for Prostate Cancer-Specific Cardiovascular RiskNickolas Stabellini, Tarek Nahle, Viraj Shah, et al.JAMA Network Open|October 15, 2024
Prior Local Therapy and First-Line Apalutamide in Patients With Nonmetastatic Castration-Resistant Prostate Cancer: A Secondary Analysis of the SPARTAN Randomized Clinical TrialSoumyajit Roy, Shawn Malone, Kevin Wing, et al.Journal for Immunotherapy of Cancer|August 16, 2023
Real-world pan-cancer landscape of frameshift mutations and their role in predicting responses to immune checkpoint inhibitors in cancers with low tumor mutational burdenVaia Florou, Charalampos S Floudas, Asaf Maoz, et al.The Oncologist|March 5, 2026
Molecular Landscape of Prostate Cancers with Clival MetastasesPornlada Likasitwatanakul, Steven M Blinka, Jabra G Zarka, et al.Cell Reports. Medicine|March 7, 2025
Phase 1 study of IMCnyeso, a T cell receptor bispecific ImmTAC targeting NY-ESO-1-expressing malignanciesJuanita S Lopez, Mohammed Milhem, Marcus O Butler, et al.Cell Reports|March 19, 2020
Cancer Cells Resist Mechanical Destruction in Circulation via RhoA/Actomyosin-Dependent Mechano-AdaptationDevon L Moose, Benjamin L Krog, Tae-Hyung Kim, et al.Pageof 21